| [1] |
World Health Organization. Global hepatitis report 2024: Action for access in low- and middle-income countries[EB/OL].( 2024-04-09)[ 2025-10-30]. https://www.who.int/publications/i/item/9789240091672. https://www.who.int/publications/i/item/9789240091672
|
| [2] |
WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J]. Gastroenterology, 2004, 126( 7): 1750- 1758. DOI: 10.1053/j.gastro.2004.03.018.
|
| [3] |
KRAMVIS A, CHANG KM, DANDRI M, et al. A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook[J]. Nat Rev Gastroenterol Hepatol, 2022, 19( 11): 727- 745. DOI: 10.1038/s41575-022-00649-z.
|
| [4] |
TU T, BUDZINSKA MA, SHACKEL NA, et al. HBV DNA integration: Molecular mechanisms and clinical implications[J]. Viruses, 2017, 9( 4): 75. DOI: 10.3390/v9040075.
|
| [5] |
ZOULIM F, CHEN PJ, DANDRI M, et al. Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome[J]. J Hepatol, 2024, 81( 6): 1087- 1099. DOI: 10.1016/j.jhep.2024.06.037.
|
| [6] |
LUCIFORA J, XIA YC, REISINGER F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343( 6176): 1221- 1228. DOI: 10.1126/science.1243462.
|
| [7] |
GUIDOTTI LG, ROCHFORD R, CHUNG J, et al. Viral clearance without destruction of infected cells during acute HBV infection[J]. Science, 1999, 284( 5415): 825- 829. DOI: 10.1126/science.284.5415.825.
|
| [8] |
PENG B, PAN LX, LI WH. New insights on hepatitis B virus viral transcription in single hepatocytes[J]. Viruses, 2024, 16( 12): 1828. DOI: 10.3390/v16121828.
|
| [9] |
WONG GL, TSE YK, WONG VW, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53, 500 subjects[J]. Hepatology, 2015, 62( 3): 684- 693. DOI: 10.1002/hep.27894.
|
| [10] |
ZHANG YY, ZHANG BH, THEELE D, et al. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver[J]. Proc Natl Acad Sci USA, 2003, 100( 21): 12372- 12377. DOI: 10.1073/pnas.2033898100.
|
| [11] |
TANG DB, ZHAO HQ, WU YM, et al. Transcriptionally inactive hepatitis B virus episome DNA preferentially resides in the vicinity of chromosome 19 in 3D host genome upon infection[J]. Cell Rep, 2021, 35( 13): 109288. DOI: 10.1016/j.celrep.2021.109288.
|
| [12] |
GUO HT, JIANG D, ZHOU TL, et al. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: An intermediate of covalently closed circular DNA formation[J]. J Virol, 2007, 81( 22): 12472- 12484. DOI: 10.1128/JVI.01123-07.
|
| [13] |
ZHAO KT, GUO FT, WANG JJ, et al. Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells[J]. Hepatology, 2023, 77( 4): 1366- 1381. DOI: 10.1002/hep.32622.
|
| [14] |
WEI L, PLOSS A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand[J]. Nat Commun, 2021, 12( 1): 1591. DOI: 10.1038/s41467-021-21850-9.
|
| [15] |
WANG YX, NIKLASCH M, LIU TT, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication[J]. J Hepatol, 2020, 72( 5): 865- 876. DOI: 10.1016/j.jhep.2019.12.009.
|
| [16] |
QI YH, GAO ZC, XU GW, et al. DNA polymerase κ is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus[J]. PLoS Pathog, 2016, 12( 10): e1005893. DOI: 10.1371/journal.ppat.1005893.
|
| [17] |
LONG QX, YAN R, HU JL, et al. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation[J]. PLoS Pathog, 2017, 13( 12): e1006784. DOI: 10.1371/journal.ppat.1006784.
|
| [18] |
ZHAO KT, WANG JJ, WANG ZC, et al. Hepatitis B virus hijacks MRE11-RAD50-NBS1 complex to form its minichromosome[J]. PLoS Pathog, 2025, 21( 1): e1012824. DOI: 10.1371/journal.ppat.1012824.
|
| [19] |
YAO QY, PENG B, LI C, et al. SLF2 interacts with the SMC5/6 complex to direct hepatitis B virus episomal DNA to promyelocytic leukemia bodies for transcriptional repression[J]. J Virol, 2023, 97( 7): e00328-23. DOI: 10.1128/jvi.00328-23.
|
| [20] |
XIA YC, CHENG XM, NILSSON T, et al. Nucleolin binds to and regulates transcription of hepatitis B virus covalently closed circular DNA minichromosome[J]. Proc Natl Acad Sci USA, 2023, 120( 49): e2306390120. DOI: 10.1073/pnas.2306390120.
|
| [21] |
SUN Y, TENG Y, WANG LY, et al. LINC01431 promotes histone H4R3 methylation to impede HBV covalently closed circular DNA transcription by stabilizing PRMT1[J]. Adv Sci, 2022, 9( 16): 2103135. DOI: 10.1002/advs.202103135.
|
| [22] |
LIU W, YAO QY, SU XN, et al. Molecular insights into Spindlin1-HBx interplay and its impact on HBV transcription from cccDNA minichromosome[J]. Nat Commun, 2023, 14( 1): 4663. DOI: 10.1038/s41467-023-40225-w.
|
| [23] |
DECORSIÈRE A, MUELLER H, van BREUGEL PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J]. Nature, 2016, 531( 7594): 386- 389. DOI: 10.1038/nature17170.
|
| [24] |
LIU F, CAMPAGNA M, QI YH, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes[J]. PLoS Pathog, 2013, 9( 9): e1003613. DOI: 10.1371/journal.ppat.1003613.
|
| [25] |
YUAN YF, ZHAO KT, YAO YX, et al. HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription[J]. Antiviral Res, 2019, 172: 104619. DOI: 10.1016/j.antiviral.2019.104619.
|
| [26] |
LUCIFORA J, ARZBERGER S, DURANTEL D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection[J]. J Hepatol, 2011, 55( 5): 996- 1003. DOI: 10.1016/j.jhep.2011.02.015.
|
| [27] |
LIU CY, ZHAO KT, CHEN YS, et al. Mitochondrial glycerol-3-phosphate dehydrogenase restricts HBV replication via the TRIM28-mediated degradation of HBx[J]. J Virol, 2023, 97( 5): e00580-23. DOI: 10.1128/jvi.00580-23.
|
| [28] |
KORNYEYEV D, RAMAKRISHNAN D, VOITENLEITNER C, et al. Spatiotemporal analysis of hepatitis B virus X protein in primary human hepatocytes[J]. J Virol, 2019, 93( 16): e00248-19. DOI: 10.1128/JVI.00248-19.
|
| [29] |
ABDUL F, DIMAN A, BAECHLER B, et al. Smc5/6 silences episomal transcription by a three-step function[J]. Nat Struct Mol Biol, 2022, 29( 9): 922- 931. DOI: 10.1038/s41594-022-00829-0.
|
| [30] |
PENG B, JING ZY, ZHOU ZM, et al. Nonproductive hepatitis B virus covalently closed circular DNA generates HBx-related transcripts from the HBx/enhancer I region and acquires reactivation by superinfection in single cells[J]. J Virol, 2023, 97( 1): e01717-22. DOI: 10.1128/jvi.01717-22.
|
| [31] |
HUANG Q, ZHOU B, CAI DW, et al. Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients[J]. Hepatology, 2021, 73( 1): 41- 52. DOI: 10.1002/hep.31240.
|
| [32] |
STADLER D, KÄCHELE M, JONES AN, et al. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20[J]. EMBO Rep, 2021, 22( 6): e49568. DOI: 10.15252/embr.201949568.
|
| [33] |
GUIDOTTI LG, ISHIKAWA T, HOBBS MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes[J]. Immunity, 1996, 4( 1): 25- 36. DOI: 10.1016/s1074-7613(00)80295-2.
|
| [34] |
SMEKALOVA EM, MARTINEZ MG, COMBE E, et al. Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo[J]. Mol Ther Nucleic Acids, 2024, 35( 1): 102112. DOI: 10.1016/j.omtn.2023.102112.
|
| [35] |
MARTINEZ MG, COMBE E, INCHAUSPE A, et al. CRISPR-Cas9 targeting of hepatitis B virus covalently closed circular DNA generates transcriptionally active episomal variants[J]. mBio, 2022, 13( 2): e02888-21. DOI: 10.1128/mbio.02888-21.
|
| [36] |
KREBS K, BÖTTINGER N, HUANG LR, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice[J]. Gastroenterology, 2013, 145( 2): 456- 465. DOI: 10.1053/j.gastro.2013.04.047.
|
| [37] |
WISSKIRCHEN K, KAH J, MALO A, et al. T cell receptor grafting allows virological control of Hepatitis B virus infection[J]. J Clin Invest, 2019, 129( 7): 2932- 2945. DOI: 10.1172/JCI120228.
|
| [38] |
GUO GL, HE WH, ZHOU ZM, et al. PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice[J]. Virology, 2023, 586: 23- 34. DOI: 10.1016/j.virol.2023.06.015.
|
| [39] |
LIU ZY, LI GP, LI XR, et al. CD163 impairs HBV clearance in mice by regulating intrahepatic T cell immune response via an IL-10-dependent mechanism[J]. Antiviral Res, 2025, 235: 106093. DOI: 10.1016/j.antiviral.2025.106093.
|
| [40] |
YANG SQ, WANG L, PAN W, et al. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance[J]. J Hepatol, 2019, 71( 4): 685- 698. DOI: 10.1016/j.jhep.2019.05.013.
|
| [41] |
SONG JJ, SUN XL, ZHOU Y, et al. Early application of IFNγ mediated the persistence of HBV in an HBV mouse model[J]. Antiviral Res, 2024, 225: 105872. DOI: 10.1016/j.antiviral.2024.105872.
|
| [42] |
LI L, BARRY V, DAFFIS S, et al. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells[J]. J Hepatol, 2018, 68( 5): 912- 921. DOI: 10.1016/j.jhep.2017.12.008.
|
| [43] |
XU XS, SHANG QH, CHEN XY, et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients[J]. Cell Mol Immunol, 2015, 12( 3): 309- 316. DOI: 10.1038/cmi.2015.25.
|
| [44] |
van BUUREN N, RAMIREZ R, TURNER S, et al. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection[J]. JHEP Rep, 2022, 4( 1): 100388. DOI: 10.1016/j.jhepr.2021.100388.
|
| [45] |
GUIDOTTI LG, INVERSO D, SIRONI L, et al. Immunosurveillance of the liver by intravascular effector CD8+ T cells[J]. Cell, 2015, 161( 3): 486- 500. DOI: 10.1016/j.cell.2015.03.005.
|
| [46] |
VENZIN V, BECCARIA CG, PERUCCHINI C, et al. CD4+ T cells license Kupffer cells to reverse CD8+ T cell dysfunction induced by hepatocellular priming[J]. Nat Immunol, 2025, 26( 8): 1352- 1366. DOI: 10.1038/s41590-025-02199-3.
|
| [47] |
ZHOU ZM, LI C, TAN ZX, et al. A spatiotemporally controlled recombinant cccDNA mouse model for studying HBV and developing drugs against the virus[J]. Antiviral Res, 2023, 216: 105642. DOI: 10.1016/j.antiviral.2023.105642.
|
| [48] |
XU ZC, ZHAO L, ZHONG YQ, et al. A novel mouse model harboring hepatitis B virus covalently closed circular DNA[J]. Cell Mol Gastroenterol Hepatol, 2022, 13( 4): 1001- 1017. DOI: 10.1016/j.jcmgh.2021.11.011.
|
| [49] |
YUEN MF, ASSELAH T, JACOBSON IM, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379(bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection(REEF-1): A multicentre, double-blind, active-controlled, randomised, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 9): 790- 802. DOI: 10.1016/S2468-1253(23)00148-6.
|
| [50] |
YUEN MF, LIM SG, PLESNIAK R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med, 2022, 387( 21): 1957- 1968. DOI: 10.1056/NEJMoa2210027.
|